areisli

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg 150 150 Lysogene Lysogene https://www.lysogene.com/wp-content/themes/crocal/images/empty/thumbnail.jpg September 25, 2020 October 20, 2020

Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update

Lysogene COVID-19 update

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

©2022 Lysogene. All rights reserved.

Get In Touch